%0 Case Reports
%T A case of complete response to avelumab plus axitinib combination therapy for metastatic clear cell renal cell carcinoma in a kidney undergoing dialysis.
%A Shiomi E
%A Goto Y
%A Hisano M
%A Ito R
%A Moriwaka M
%A Ikarashi D
%A Maekawa S
%A Kato R
%A Kanehira M
%A Ujiie T
%A Obara W
%J IJU Case Rep
%V 7
%N 2
%D 2024 Mar
%M 38440696
暂无%R 10.1002/iju5.12689
%X <B>UNASSIGNED: </B>Combination therapies of immune checkpoint and tyrosine kinase inhibitors for end-stage kidney disease and patients on hemodialysis need careful consideration as few case reports provide suitable management decisions.<BR><B>UNASSIGNED: </B>A 70-year-old man who had undergone hemodialysis for 6 years due to nephrosclerosis. Avelumab plus axitinib combination therapy was performed for repeated lung metastasis, and a complete response was achieved without major side effects.<BR><B>UNASSIGNED: </B>A complete response was achieved after Ave plus Axi combination therapy for clear cell renal cell carcinoma in a patient undergoing dialysis. This suggests that Ave plus Axi combination therapy may be safe and effective for dialysis patients.